XTL Biopharmaceuticals Ltd. has entered into a binding letter of intent with Beyond Air, Inc. for the proposed acquisition of NeuroNOS Ltd., a private Israeli biopharmaceutical company focused on developing treatments for Autism Spectrum Disorder, Alzheimer’s disease, and brain cancers. Under the agreement, Beyond Air, which currently holds 85% of NeuroNOS, will receive American Depositary Shares representing 19.99% of XTL’s outstanding share capital, three-year warrants to maintain this ownership level, a $1 million cash payment within 60 days of closing, and potential milestone payments up to $5.5 million or a single lump sum of $4 million. Additional commercial milestone payments ranging from $2 million to $12.5 million are also contingent on cumulative net sales of the first NeuroNOS product. XTL intends to offer the remaining NeuroNOS shareholders the opportunity to exchange their shares for XTL ordinary shares after the transaction closes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003672), on January 13, 2026, and is solely responsible for the information contained therein.